Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02317991
Other study ID # SCRI GI 201
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 5, 2015
Est. completion date May 21, 2021

Study information

Verified date June 2022
Source SCRI Development Innovations, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether nab-Paclitaxel (Abraxane®) and ramucirumab (Cyramza®) are effective when used in combination for treating patients with metastatic gastroesophageal cancer who have either progressed or not responded to prior therapy.


Description:

Adenocarcinoma of the esophagus and the gastroesophageal junction (GE junction) is the ninth most common cancer worldwide. Ramucirumab (Cyramza®), a monoclonal antibody, is approved as a single agent and in combination with paclitaxel as a treatment for patients with metastatic gastric or GE junction adenocarcinoma whose cancer has progressed after prior chemotherapy. Nab-paclitaxel (Abraxane®) is an albumin-based formulation of paclitaxel which was developed to improve the therapeutic index and reduce toxicity. Nab-paclitaxel is approved in over 40 countries/regions for treatment of various metastatic cancers including breast cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer. In this Phase II study, the investigators propose to combine the less toxic nab-paclitaxel to increase tumor uptake of the drug and improve efficacy while minimizing side effects. The biological rationale of using this combination is that ramucirumab will inhibit tumor angiogenesis and nab-paclitaxel will induce apoptosis of the rapidly dividing tumor cell.


Recruitment information / eligibility

Status Completed
Enrollment 65
Est. completion date May 21, 2021
Est. primary completion date May 21, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients with histologically confirmed metastatic adenocarcinoma of the esophagus, GE junction, or stomach who progressed on one prior line of chemotherapy in the metastatic setting. 2. Measurable disease as measured by Response Evaluation Criteria in Solid Tumors (RECIST) criteria Version 1.1. 3. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 4. Adequate hematologic, renal, and hepatic functions 5. Patients must have < Grade 2 pre-existing peripheral neuropathy (per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v 4.03) 6. Life expectancy > 3 months Exclusion Criteria: 1. Patients who have received any other investigational agents, chemotherapy, biologic therapy, or radiation therapy within the 28 days prior to Day 1 of the study. For investigational, chemotherapy, or biologic therapy, patients will be allowed on study if five half-lives or greater have elapsed since last dose of drug or 28 days, whichever is shorter. 2. Patients with prior taxane chemotherapy or agents which act by primary anti-angiogenic mechanisms. 3. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit safety or compliance with study requirements or may interfere with the interpretation of the results. 4. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study initiation, or anticipation of need for major surgical procedure during the course of the study. 5. Evidence or history of uncontrolled hypertension, proteinuria, non-healing wound, ulcer, bone fracture, hemoptysis, valvular disease, abdominal fistula, GI perforation, intra-abdominal abscess, bleeding diathesis or coagulopathy that would exclude patients from treatment with anti-angiogenesis agents. 6. Therapeutic anticoagulation with coumarin-derivatives will not be permitted. However, a maximum daily dose of 1 mg will be permitted for port line patency. Anticoagulation with low molecular weight heparin or anti-Factor Xa agents will be allowed. 7. Patients with other concurrent severe and/or uncontrolled medical disease which could compromise safety of treatment as so judged by treating physician (i.e., severely impaired lung function, severe infection, ventricular arrhythmias active ischemic heart disease, known active vasculitis of any cause, chronic liver or renal disease).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
nab-paclitaxel
nab-paclitaxel 125 mg/m^2 IV
Biological:
ramucirumab
Ramucirumab 8 mg/kg IV

Locations

Country Name City State
United States Tennessee Oncology Chattanooga Tennessee
United States Oncology Hematology Care Cincinnati Ohio
United States Rocky Mountain Cancer Centers Denver Colorado
United States Florida Cancer Specialists-South Fort Myers Florida
United States Center for Cancer and Blood Disorders Fort Worth Texas
United States Ingalls Cancer Research Center Harvey Illinois
United States Research Medical Center Kansas City Missouri
United States Tennessee Oncology PLLC Nashville Tennessee
United States Florida Hospital Cancer Institute Orlando Florida
United States Florida Cancer Specialists-North Saint Petersburg Florida
United States Spartanburg Medical Center/Gibbs Cancer Center Spartanburg South Carolina

Sponsors (2)

Lead Sponsor Collaborator
SCRI Development Innovations, LLC Celgene

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Number of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability Adverse events will be graded utilizing the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 For duration of treatment, up to of 6 months
Primary Progression-Free Survival (PFS) Measured from Day 1 of study drug administration to disease progression as defined by Response Evaluation in Solid Tumors Criteria (RECIST v1.1), or death on study from any cause. Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Participants who are alive and free from disease progression were censored at the date of the last adequate tumor assessment. If no adequate post-treatment tumor assessments were obtained for participants, PFS will be censored on Day 1. up to 1 year
Secondary Overall Response Rate (ORR) ORR is defined as the percentage of patients with confirmed complete response (CR) or confirmed partial response (PR), i.e., two CRs and/or PRs at least 4 weeks apart, according to the RECIST v1.1 criteria. CR=disappearance of all target lesions. PR=at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. every 8 weeks up to 1 year
Secondary Time to Progression (TTP) TTP is defined as the time from the first day of study drug administration (Day 1) to objective disease progression as defined by the RECIST v1.1 criteria. Patients who are alive and free from disease progression will be censored at the date of the last adequate tumor assessment. If no adequate post-treatment tumor assessments were obtained for a patient, TTP will be censored on Day 1. Progressive Disease (PD): At least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or unequivocal progression of non-target lesions or the appearance of one or more new lesions. up to 1 year
Secondary Overall Survival (OS) OS is defined as the time from the first treatment until date of death due to any cause. In the absence of confirmation of death or lack of data beyond follow-up period, the survival time was censored to last date the participant was known to be alive. up to 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04544046 - Supportive Oncology Care At Home RCT N/A
Not yet recruiting NCT04555304 - Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy Phase 2
Terminated NCT02669914 - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Phase 2
Completed NCT04099641 - An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients Phase 2
Not yet recruiting NCT05431738 - Anti-Migration System for Anti-reflux Oeso-gastric Stent (ANTIMIG) N/A
Recruiting NCT04385641 - Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer N/A
Completed NCT03165994 - APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers Phase 2
Active, not recruiting NCT03279237 - A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers Phase 1
Completed NCT03321630 - A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies Phase 2
Completed NCT02853474 - Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy Phase 3
Recruiting NCT05620134 - Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer Phase 1/Phase 2
Active, not recruiting NCT03983954 - Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors Phase 1
Active, not recruiting NCT06138223 - The Effect of exeRcise And Diet on Quality of Life in Patients With Incurable Cancer of Esophagus and Stomach (RADICES) N/A
Active, not recruiting NCT03647969 - Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT05122091 - Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma Phase 2
Completed NCT03720678 - A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies Phase 1
Completed NCT02013154 - A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab Phase 1
Terminated NCT05395052 - FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors Phase 1
Recruiting NCT06356311 - A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) Phase 3
Active, not recruiting NCT03490292 - Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer Phase 1/Phase 2